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1. Introduction  
The process of angiogenesis consists in the sprouting of new blood vessels from existing 
ones. This is a natural process that occurs in the human body and is essential for organ 
growth and repair. In the embryonic stage, the blood vessels provide the necessary oxygen, 
nutrients and instructive trophic signals to promote organ morphogenesis (Coultas et al., 
2005). After birth the angiogenic process only contributes to organ growth and during 
adulthood the angiogenic process only occurs in the placenta during the pregnancy and in 
the cycling ovary, while most blood vessels remain quiescent. However the angiogenic 
activity could be reactivate because endothelial cells retain their angiogenic activity in 
response to a physiological stimulus (wound healing and repair) (Alitalo et al., 2005).  
This angiogenic activity is also critical in the development of solid tumors and metastasis 
(Ferrara, 2004; Folkman, 1990). Generally, a solid tumor expands until 1-2 mm3 is reached. 
At this point vascularization is required in order to ensure a supply of nutrients, oxygen, 
growth factors and proteolytic enzymes to the tumor (Folkman, 1990). To activate the 
angiogenic activity of endothelial cells, the tumor switches to an angiogenic phenotype and 
recruits blood vessels from the surrounding tissue, developing a dense vasculature that 
provides nutrients to the cancerous tissue (Figure 1). Numerous proangiogenic proteins are 
involved in tumor angiogenesis.  
Two of the most important families of pro-angiogenic proteins are the vascular endothelial 
growth factors (VEGF) and the fibroblast growth factors (FGF) (Garcia-Fernandez et al., 2010c). 
Most of these GF isoforms (this is not the case of the smallest isoform of VEGF-A (V121), that 
does not present a heparin-binding domain) need to interact with heparan sulfate 
proteoglycans molecules (HSPG) in order to recognize their specific tyrosine kinase receptor 
on cell membrane and activate the angiogenic process. These cell surface molecules are low 
affinity receptors that do not transmit a biological response, but are essential for these growth 
factors to recognize their union site to the signaling receptor (FGFR or VEGFR). Therefore, 
disruption of the interaction of these growth factors (GF) with cell surface HSPG seems an 
evident target for angiogenesis (Folkman, 1971; Folkman, 1990; Folkman, 1995). 
HSPGs are heparin-like molecules that favor the pro-angiogenic proteins oligomerization 
(Figure 1), which is necessary for the interaction with the endothelial cells membrane 
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receptors. Heparin is a natural polysaccharide composed of alternating units of sulphated 
glucuronic acid and glucosamine derivatives, it presents anticoagulant activity and interacts 
with the most important pro-angiogenic proteins in tumor angiogenesis (e.g. different 
isoforms of FGF and VEGF) (Fernández-Tornero et al., 2003; Lindahl et al., 1994).  
 
 
Fig. 1. Structure of a heparin-linked biologically active dimer of acidic fibroblast growth 
factor. Heparin is shown as stick-and-ball model (carbon: grey; oxygen: red; sulfur: yellow; 
nitrogen: blue). The figure was generated and the surfaces colored according the 
electrostatic potential (red, negative; blue, positive) using OpenAstexViewer (3.0; Astex 
Therapeutics Ltd.) and its internal parameters. PDB ID: 1AXM  (DiGabriele et al., 1998).  
The interaction between heparin and “heparin binding-proteins” (those that present a 
heparin-binding domain) regulates most of the biological properties of this sulfated 
glycosaminoglycan (GAG). However, angiogenesis is a complicated process regulated by 
numerous biologically active molecules and through different pathways that cannot be 
explained without each other (Figure 2). The ideal heparin-like drug to be designed for the 
treatment of tumor angiogenesis not only will interact with angiogenic growth factors 
(FGF-1, FGF-2, VEGF...) reducing their functional activity, but also will inhibit heparanase 
preventing the release of these growth factors from the extracellular matrix (ECM) and 
stimulate tissue factor pathway inhibitor (TFPI) conferring an antimetastatic character to the 
molecules. Heparanase is an endo--D-glucuronidase capable of cleaving the heparan 
sulfate (HS) side chains of HSPG, playing a key role in ECM-remodelling and heparin-
binding release, and TFPI is a potent anticoagulant and antiangiogenic endogenous 
polypeptide.  
In this chapter, the most recent studies for the design of heparin-like drugs will be reviewed 
starting with the effect of different heparinoids (low molecular weight heparins (LMWH) and 
chemically modified heparins) and finishing with the activity of synthetic antiangiogenic 
molecules. Many of these studies demonstrate that the biological activity of these heparin-
like drugs depends on composition (charge density), microstructure (charge distribution),  
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molecular weight, and the supramolecular organization (charge orientation) of the polymers 
(Garcia-Fernandez et al., 2010b; Garcia-Fernandez et al., 2010c). Most of the clinically 
investigated therapies target VEGF or one of its receptors (e.g. Bevacizumab or Avastin, a 
recombinant humanized monoclonal IgG1 (anti-VEGF-A) antibody) (Wahl et al., 2011), 
however the development of new compounds that interact with pro-angiogenic molecules 
through heparin-binding domains is a good strategy to obtain new therapeutics with 
synergistic inhibitory effect of not one but several pro-angiogenic molecules (broad-
spectrum angiogenesis inhibitors).  
 
Interact with proangiogenic
heparin-binding GF
(FGF-1, FGF-2, VEGF)
GF functional activity is reduced
Inhibit
ANGIOGENESIS
Inhibit heparanase
Enzymatic degradation of ECM
and subsequent release of 
proangiogenic heparin-binding GF is inhibited
Inhibit
METASTASIS
Stimulate TFPI release
Enzymatic degradation of ECM
and subsequent release of 
proangiogenic heparin-binding GF is inhibited
Heparin-like drug
 
Fig. 2. Possible effects of heparin-like drugs for the treatment of tumor angiogenesis: 
interaction with proangiogenic heparing-binding growth factors, inhibition of heparanase 
and stimulation of TFPI release.  
2. Heparin species (heparinoids) 
Heparin presents very interesting pharmacological actions including antitumor and 
antimetastatic activity, however its use as anticancer agent has been limited due to the high 
risk of bleeding complications because of its anticoagulant and antithrombotic properties. 
Several efforts have been performed in the last decades in order to mimic and specifically 
modulate the biological action of heparin by exogenous heparin species (i.e. unfractionated 
heparin, LMWH, heparin oligosaccharides, chemically modified heparins and 
biotechnologically obtained heparins). Fortunately, heparin modification allowed the 
creation of new heparinoids with non-anticoagulant activity but antiheparanase activity and 
ability to interact selectively with proangiogenic growth factors. As it will be demonstrated 
molecular weight, charge density and charge distribution of heparin play a key role in its 
biological activity.  
2.1 Low molecular weight heparins (LMWH) 
LMWH are derived from unfractionated heparin (UFH) by chemical or controlled enzymatic 
depolymerization and present a lower mean molecular weight between 3 and 6 kDa and 
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chain lengths of 12 to 18 saccharide units. LMWHs have been available in Europe since the 
mid-1980s. In 1993 the first LMWH was approved in the United States for the treatment of 
venous thrombus (Grande & Caparro, 2005; Kakkar, 2004). 
Since are prepared by different methods of depolymerization, they differ to some extent in 
pharmacokinetic properties and anticoagulant profile, and may not be clinically 
interchangeable (Hirsh et al., 2001; Norrby, 2006).  
LMWH present important advantages if compared to UFH: enhanced bioavailability after 
subcutaneous administration, prolonged half-life and more interesting pharmacokinetic 
properties, reduced thrombocytopenia and a more predictable dose response (Grande & 
Caparro, 2005; Khorana et al., 2003). 
 
Generation 
heparin 
Name 
Commercial 
name 
Method of  
preparation 
Mean 
molecular 
weight (Da)
References 
First 
generation 
heparin 
Tinzaparin Innohep Heparinase 
depolymerization
6.500 
 (Amirkhosravi et al., 2003; 
Gasowska et al., 2009; Mousa 
& Mohamed, 2004a; Mousa & 
Mohamed, 2004b; Mousa & 
Petersen, 2009; Norrby, 2006) 
Dalteparin Fragmin 
Nitrous acid 
depolymerization 6.000 
 (Khorana et al., 2003; 
Marchetti et al., 2008; Norrby, 
2006; Norrby & Nordenhem, 
2010; Takahashi et al., 2005) 
Enoxaparin Clexane 
Benzylation and 
alkaline 
hydrolysis 
4.500 
 (Khorana et al., 2003; 
Marchetti et al., 2008; Norrby, 
2000; Norrby, 2006) 
Nadroparin Fraxiparin 
Nitrous acid 
depolymerization
4.500 
 (Debergh et al., 2010; Khorana 
et al., 2003; Norrby, 2000) 
Reviparin Clivarine 
Nitrous acid 
depolymerization
4.500 
 (Collen et al., 2000; Gasowska 
et al., 2009; Mousa & Petersen, 
2009; Norrby, 2006) 
Second 
generation 
heparin 
Bemiparin Badyket 
Chemical β-
elimination 
depolymerization
3.500 
 (Depasse et al., 2003; Dogan et 
al., 2011; Jeske et al., 2011; 
Perez-Ruiz et al., 2002; Vignoli 
et al., 2011; Westmuckett et al., 
2001) 
ULMWH 
 (RO-14) 
--- 
Chemical β-
elimination 
depolymerization
2.200  (Vignoli et al., 2011) 
Table 1. LMWH and ULWMW with antiangiogenic activity. 
These advantages have led to their increasing use in the treatment of cancer as angiogenesis 
inhibitors. Clinical studies suggest a significant mortality reduction in cancer patients 
receiving different heparin fractions for the treatment of venous thromboembolism versus 
those receiving UFH (Akl et al., 2008). However, conflicting data have been presented in 
different clinical studies and at present there is not approved use of LMWH for survival 
gain in cancer patients without a need for venous thromboembolism prophylaxis or 
treatment (Kakkar, 2004; Kwaan et al., 2009; Mousa & Petersen, 2009; Norrby, 2006; Sideras 
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et al., 2006; Thodiyil & Kakkar, 2002). Therefore, the potential role of LMWH heparin 
requires additional clinical evaluation. In particular, these studies should focus on 
identifying which type and stage of cancer that are most likely to respond to this form of 
therapy, as well as on optimizing the dose and duration of treatment (Robert, 2010). 
As mentioned in the introduction, angiogenesis is a complex multistep process involving 
activation, proliferation and migration of endothelial cells, degradation of ECM by 
proteolytic enzymes (e.g. heparanase) and formation of the capillary vessel lumen (Marchetti 
et al., 2008). Moreover, tissue factor (TF) and its natural inhibitor (TFPI) are also important 
heparin-binding proteins that perform well-recognized roles in the regulation of 
angiogenesis, tumor growth and metastasis (Bobek & Kobarik, 2004; Borsig, 2010; Debergh 
et al., 2010; Norrby, 2006). LMWH may influence angiogenesis through modulation of the 
expression of angiogenic growth factors (VEGF and bFGF) and their inhibitors (Dogan et al., 
2011; Gasowska et al., 2009; Mousa & Petersen, 2009).  
LMWH can be classified according to their molecular weight into first generation and 
second generation, as show in table 1 (Hirsh et al., 2001; Vignoli et al., 2011). 
2.1.1 First generation heparins 
First generation LMWH present an average molecular weight between 4 and 6 kDa and both 
antiangiogenic and anticoagulant properties (Hirsh et al., 2001; Mousa & Petersen, 2009; 
Vignoli et al., 2011). Representative examples are dalteparin, tinzaparin, enoxaparin, 
nadroparin and other heparin fractions in the range of this mean molecular weight. In 
addition to differences in average molecular sizes, these LMWH differ on sulfation density 
and distribution of the sulfate groups along the macromolecular chains due to the 
manufacturing process. These differences influence to their antiangiogenic potentials and 
the possible anticancer mechanism (Norrby, 2006). 
The main mechanism underling the antiangiogenic effect of the LMWHs is based on their 
interaction with the heparin-binding site of VEGF and bFGF and the subsequent inhibition 
of their cellular receptors (VEGFR and FGFR) (Bobek & Kovarik, 2004; Debergh et al., 2010; 
Gasowska et al., 2009; Mousa & Petersen, 2009). 
Norrby and Nordenhem  investigated if dalteparin (Fragmin, 6kDa), epirubicin as an 
important chemotherapeutic agent or a combination of these two drugs modulated 
angiogenesis in vivo by rat mesentery assay (Norrby & Nordenhem, 2010). Heparins were 
administrated by subcutaneous infusion at different concentration during 14 days. In these 
conditions, the effects on VEGF-mediated angiogenesis were measured. Dalteparin 
significantly stimulated angiogenesis in an inversely dose-dependent manner. The lowest 
concentration of 27 IU/kg/day produced the maximum increase the microvascular length 
(MVL) by 25% and total microvascular length (TMVL) by 71%. On the other hand, 
epirubicin did not significantly affect angiogenesis. However, concurrent treatment with the 
two drugs significantly inhibited angiogenesis. Particularly, the MVL decreased by 24% and 
the TMVL by 45%, using injection of epirubicin at 3 mg/kg/week and dalteparin at 
80 IU/kg/day. This appears to be the first demonstration that LMWH in its own is able to 
increase angiogenesis in vivo. Recently, it was reported that UFH and dalteparin exerted 
similar effects on angiogenesis using the Matrigel plug assay in mice (Takahashi et al., 2005). 
On the other hand, Marchetti et al. studied how LMWHs affected the angiogenic potential of 
human microvascular endothelial cells (hMVEC) promoted by different tumor cells as well 
as growth factors (VEGF and FGF-2). Dalteparin, and enoxaparin (Clexane, 4.5 kDa) were 
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selected on the basis of their different molecular weight range and manufacture process, as 
these characteristics are thought to affect their pharmacokinetic and biological properties 
(Hirsh et al., 2001). The angiogenesis inhibition was evaluated by in vitro capillary-like tube 
formation assay in Matrigel. The results demonstrated both LMWHs significantly inhibited 
microvascular endothelial cells capillary-like tube formation when induced by human breast 
cancer and leukemia cells, while a lower inhibitory effect was observed with UFH (100% 
inhibited by enoxaparin, 70-90% by dalteparin and only 25-33% by UHF, depending on the 
considered growth factor). These results indicated that these heparins played an important 
role in VEGF mediated capillary formation (Marchetti et al., 2008). 
Recent clinical studies have shown the effect of dalteparin in the treatment of patients with 
cancer. In the Fragmin Advanced Malignancy Outcome Study (FAMOUS) 385 patients with 
advanced solid tumor malignancy were randomly assigned either a once-daily 
subcutaneous injection of the dalteparin in a dose of 5000 units or placebo for 1 year. The 
study demonstrated a 5% survival advantage at 1 year in favour of the advanced cancer 
patients who received dalteparin. These findings have been further confirmed in other 
clinical trials (Bick, 2006; Kakkar, 2004; Kakkar et al., 2004; Kwaan et al., 2009).  
The differential effects of LMWHs compared to UFH on angiogenesis seem to be depending 
on the size of the molecule and number of saccharide units. It has been shown that LMWH, 
in contrast to UFH, can reduce binding of growth factors to their receptors. Based on these 
findings, the lower mean molecular weight of enoxaparin compared to dalteparin should be 
responsible for the higher inhibitory effect of capillary tube formation (Khorana et al., 2003; 
Marchetti et al., 2008). 
Similarly, Khorana et al. demonstrated that molecules with a molecular weight in the range 
of 3-6 kDa or more than 8 saccharide units maximally inhibited angiogenesis in a Matrigel 
assay using human umbilical vein endothelial cells (HUVECs). Specifically, fraction of 6 and 
3 kDa inhibited FGF-proliferation by 94 and 60%, respectively.  However, the measure of 
heparin fractions of lower molecular weight, as 2.4, 1.7 and 1.2 kDa, showed no significantly 
inhibition of proliferation. Moreover, the time of action and the concentration of heparin 
fraction were optimized, determining that the maximum capacity inhibition of 6 kDa 
fraction was at 72 hours and 5 µg/ml.  
On the other hand, the results showed that heparins fractions with the same range of 
molecular weight also reduced tube formation through the organization into tubular 
structures (3 and 6 kDa heparin fractions decreased the formation of capillary-like tube 
structures between 58 and 78%, respectively). Chain length and molecular weight 
significantly affect other functional properties such as bioavailability after subcutaneous 
administration, half-life, binding proteins or anticoagulant activities.  
Norrby et al. studied the effect of heparin fractions on the microcapillary sprouting in 
angiogenesis mediated by VEGF using a rat mesenteric window assay. Heparin fragments 
with molecular weight of 2.5 to 5 kDa reduced the number of microvessel and branching 
points per unit tissue volume more effectively than 16.4 kDa fraction (Norrby, 2000). On the 
other hand, FGF-mediated angiogenesis was more intensely suppressed by 2.6 kDa fraction 
compared with 4 fractions of higher molecular weight. The heparins fraction in this study 
varied in charge density and anticoagulant activity (Khorana et al., 2003). In this sense, it is 
important to emphasize that the anticoagulant properties of heparins are related to chain 
length, as reflected by the increased anti-Xa/anti-IIa activity of LMWHs (Figure 3) (Bobek & 
Kovarik, 2004; Grande & Caparro, 2005; Hirsh et al., 2001). Other authors demonstrated that 
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heparin fragments with less than 18 saccharides hinder the activity of VEGF and those with 
less than 10 saccharides reduce bFGF activity (Bobek & Kovarik, 2004; Debergh et al., 2010; 
Dogan et al., 2011).  
Debergh et al. studied the effects of nadroparin (Fraxiparin, 4.5 kDa) on tumor-associated 
angiogenesis, using a dorsal skinfold window chamber model in the Syrian hamster. Active 
angiogenesis was observed in control animals, however nadroparin inhibited tumor-
associated angiogenesis and normalized microvessel structure in this immunocompetent 
tumor model (Debergh et al., 2010).  
Klerk et al. evaluated the effect of nadroparin on survival in patients with advanced 
malignancy based on time from random assignment to death. At 6 months the survival was 
61% in the nadroparin group versus 56% in the placebo group indicating that a brief 6-week 
course of subcutaneous nadroparin favourably influences the survival in patients with 
advanced solid malignancy (Klerk et al., 2005; Kwaan et al., 2009). 
It is important to consider that angiogenesis is a multi-step process. Tumoral cells activate 
blood coagulation involving procoagulant factors, such as the tissue factor (TF).  TFPI is a 
natural inhibitor of this procoagulant factor that suppresses a number of steps in the 
angiogenic process. TFPI is a heparin-binding protein. Particularly, LMWH suppress the 
activity of the TF and release of TFPI which appear to inhibit tumor growth (Amirkhosravi 
et al., 2003; Bobek & Kovarik, 2004; Gasowska et al., 2009; Kuczka et al., 2009; Mousa & 
Petersen, 2009; Vignoli et al., 2006). Recent studies demonstrated that the inhibition of 
angiogenesis through the TFPI release is dependent on the molecular size of the heparin 
used. Tinzaparin (Innohep, 6.5 kDa) is especially effective at releasing TFPI (Amirkhosravi et 
al., 2003; Hirsh et al., 2001). Preclinical in vitro studies have shown that the higher the 
molecular weight and degree of sulfation of tinzaparin fractions, the higher the angiogenesis 
inhibition by control of TFPI (Mousa & Mohamed, 2004b; Mousa & Petersen, 2009; Norrby, 
2006). 
Several trials have confirmed clinical efficacy and tolerability of tinzaparin, including in 
cancer patients where tinzaparin was found more effective and as safe as warfarin (a 
commonly used anticoagulant) for long-term treatment (Kwaan et al., 2009).  Amirkohsravi 
et al. investigated the effect of tinzaparin on long metastasis using a B16 melanoma model in 
experimental mice. The results indicated that administration of tinzaparin strongly inhibits 
tumor-associated coagulopathy and experimental metastasis. In particular, the injection of 
10 mg/kg of tinzaparin significantly decreased the number of lung tumor modules from 30 
with controls to only 3. Additionally, a second injection of the same dose of heparin during 
14 days reduced the tumor mass by 96%. The favorable pharmacokinetic attributed to this 
agent compared to UFH, together with its superior ability to release TFPI for relatively long 
periods from vascular endothelial cells, provide a rationale for its use in oncology as a 
metastatic as well as an antiangiogenic agent (Amirkhosravi et al., 2003). As TF is involved 
in tumor angiogenesis through the regulation of VEGF expression, it could be hypothesized 
that heparins can interfere with the angiogenic process through TF downregulation as well 
(Debergh et al., 2010; Kuczka et al., 2009; Marchetti et al., 2008; Mousa & Petersen, 2009; 
Vignoli et al., 2006). 
Other important first generation heparins are certoparin (6.0 kDa) (Kwaan et al., 2009; 
Norrby, 2006) and reviparin (Clivarine, 4.5 kDa) (Hirsh et al., 2001; Norrby, 2006). 
Tempelhoff et al. studied whether cancer mortality in women with previously untreated 
breast and pelvic cancer is reduced in those who randomly received certoparin compared to 
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patients treated with UFH. Survival in the patients with certoparin treatment was 
significantly improved after 650 days for pelvic cancer. Particularly, the mortality rate was 
9% in the certoparin group versus 29% in the patients with UFH treatment (Von Tempelhoff 
et al., 2000).  
Pross et al. studied the influence of reviparin at different concentration (0.55, 1.10 and 2.76 
mg/ml) on the intraabdominal tumor growth through in vitro Matrigel assay and in vivo 
experiments with rats. After application of reviparin, an important inhibition of tumor cells 
adhesion was observed, particularly with the highest concentration used (1.6·105 cells were 
measured in the control group, whereas the number of cells were 0.36·105 with the 
reviparin). Moreover, the invasive potential was reduced to more than 50% for all 
concentrations of heparin. On the other hand, a combination of peritoneal and subcutaneous 
administration of reviparin reduced tumor growth in rats to higher concentrations of 
4 mg/ml (Mousa & Petersen, 2009; Norrby, 2006; Pross et al., 2003).  
Collen et al. evaluated the effects of reviparin and UFH on growth factor-induced 
proliferation and the formation of capillary-like tubular structures by hMVEC. Reviparin 
inhibited the proliferation of hMVEC induced by angiogenic factors bFGF and VEGF and 
affected fibrin matrix formation. Particularly, reviparin enabled the formation of more rigid 
and fine fibrin fibers, whereas UFH caused the formation of thick and porous fibers. These 
results may indicate a novel mechanism by which LMWHs affect tumor angiogenesis. 
However, contradictory results have been described in recent studies (Bobek & Kovarik, 
2004; Collen et al., 2000; Gasowska et al., 2009; Norrby, 2006). 
2.1.2 Second generation heparins 
Recently, the second generation LMWHs is being investigated. These new generation of 
heparins are characterized by a lower mean molecular weight, a more precisely defined 
composition of polysaccharidic chains and better anti-Xa/anti-IIa ratio. The first generation 
LMWHs had between 25 and 50% of fragments with 18 or more saccharides. However, the 
new generation of heparins contains a significant lower percentage of long chains, 
improving their therapeutic action and reduce the problems of coagulation and bleeding. 
Moreover, these properties may lead to a more favorable behavior as regards the efficacy / 
safety ratio. The comparison of the properties of first and second generation heparins is 
shown in Figure 3 (Norrby, 2006). 
 
   
Fig. 3. Molecular weight vs antiXa/antiIIa ratio and molecular weight vs half-life.  
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Bemiparin (Badyket, 3.5 kDa) (Balibrea et al., 2007; Dogan et al., 2011; Jeske et al., 2011; 
Vignoli et al., 2011) has been available in Europe for 10 years but only recently has been 
evaluated in clinical trials to determine its angionenic potential in patients with cancer. The 
efficacy of bemiparin administration in patients limited small cell lung cancer was evaluated 
in the ABEL study. Randomized patients received homogeneous treatment with 
chemotherapy or standard treatment plus bemiparin during 26 weeks.  The administration 
of bemiparin significantly improved the clinical outcome in patients with cancer. 
Particularly, after several months of treatment, 77% of the bemiparin group patients were 
alive compared to 20% of the control group. Moreover, significant survival advantages have 
been demonstrated when this molecule was co-administrated with chemotherapeutic 
agents.  
Ultralow molecular weight heparins (ULMWH), such as RO-14, (2.2kDa) are currently in 
clinical developmental phase. The aim of these early studies is to evaluate the safety and 
pharmacodynamic profile of ULMWH. Rico et al. conducted a complete randomized study 
with two cohorts of volunteers to determine the pharmacodynamic properties of RO-14. The 
results indicated that RO-14 has a good anti-Xa activity (80-140 IU/mg), a higher half-life 
than other marketed LMWH (between 5 and 8 hours compared with 2 – 4 hours for 
dalteparin, enoxaparin or tinzaparin) and is characterized by its non-anti-IIa activity (< 10 
IU/mg versus 58 IU/mg of dalteparin, for example)  (Rico et al., 2011). 
Since the antiangiogenic properties of heparin fractions depend on the average molecular 
weight and the composition of their polysaccharidic chains, it is necessary to evaluate the 
angiogenesis effect of the second generation heparins. According to recent studies, 
bemiparin and RO-14 appear to be effective in preventing and inhibiting angiogenesis in in 
vitro assays (Bosch et al., 2010). 
Vignoli et al. determined the angiogenesis inhibition of the bemiparin and RO-14 by in 
vitro capillary-like tube formation assay in Matrigel. The experiments were performed 
using tumor-cell-conditioned media (TCM) from different tumor cell lines as well as 
growth factors (VEGF and FGF-2). In these conditions, heparins decreased tube formation 
induced by TCM, between 82 – 100% at 10 IU/ depending on the tumor cell line used. 
Moreover, capillary-like tube formation induced by growth factors was 100% inhibited at 
the highest concentration of heparin used. These complete results indicate a possible role 
of these molecules as adjuvant drugs in cancer treatment and suggest that the 
antiangiogenic inhibition can be remained by heparins with a lower molecular weight and 
shorter polysaccharidic chains (Vignoli et al., 2010; Vignoli et al., 2007; Vignoli et al., 
2011). 
Different authors have shown that bemiparin increases the release and activity of TFPI from 
endothelial cells  (Planès, 2003; Sánchez-Ferrer, 2010; Vignoli et al., 2011). In addition, recent 
studies have demonstrated that bemiparin has a better control over this factor compared to 
UFH and first generation heparins such as dalteparin.  (Perez-Ruiz et al., 2002; Westmuckett 
et al., 2001) 
Westmuckett et al. studied the release and expression of TFPI in endothelial cells under 
static conditions and arterial sheer stress with the therapeutic action of bemiparin compared 
with dalteparin and UFH. In all experiments, bemiparin showed the most important cellular 
TFPI activity. On the other hand, the three types of heparin enhanced the expression of TFPI 
by 60 to 120% under static conditions and this increase only was possible with bemiparin 
under arterial stress. Perez-Ruiz et al. compared the TF activity of bemiparin and UFH using 
human umbilical vein endothelial cells (HUVEC). Samples were prepared with the addition 
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of heparins at 1 or 10 IU/ml and measured after 2, 6, and 24 hours. Only both concentrations 
of UFH produced a significant enhance of TF expression. 
However, conflicting data have been presented in different studies. Depasse et al. studied the 
TFPI release profiles of bemiparin and tinzaparin through their subcutaneous administration 
to randomized volunteers. These parameters were performed by using ELISA total and free 
TFPI kits. The results indicated that bemiparin experimented more rapid and potent 
antithrombotic (antiXa) activity but the TFPI release was significantly lower than with 
tinziparin. Particularly, the mean maximum free TFPI was 70 ng/ml after the injection of 
tinzaparin but only 30 ng/ml in the case of bemiparin. The differences in the average 
molecular weight and sulfation degree may influence these behaviours (Depasse et al., 2003).  
Recent studies compare the angiogenic effect of the bemiparin with others first generation 
LMWH in the chick embryo chorioallantoic membrane (CAM) model. This in vivo study 
used different concentrations of heparins (1, 10, and 100 IU/10 l) and measured the 
decrease of vessel formation using stereoscopic microscope. The results demonstrated that 
bemiparin, enoxaparin, nadroparin and tinzaparin have antiangiogenic effects on CAM, 
being more significant in high concentrations (100 IU/10 µl). Moreover, nadroparin and 
tinzaparin have also substantial antiangiogenic effects at the moderate concentration of 10 
IU/10 µl as a result of their higher antiangiogenic potential. A possible categorization of 
LMWHs in this context would facilitate the choice of drug that would be used in further 
experimental and clinical research (Dogan et al., 2011). 
Actually, new ULMWHs are investigated as semuloparin (2.5 kDa) with a half-life of 16-20 
hours that allows one daily subcutaneous injection. It is produced using a novel 
depolymerization reaction with high selectivity. Jeske et al. compared the biological activity 
of semuloparin and bemiparin through coagulation and pharmacological assays. The results 
of this study indicated that the differences in the oligosaccharide composition and 
manufacturing process may influence biological activity such as protein interactions with 
growth factors. Moreover, these differences may translate into a different clinical safety-
efficacy profile (Jeske et al., 2011). 
2.2 Chemically modified heparins 
Chemical modification of heparin has become a potent strategy to obtain new compounds 
with different biological properties from the original GAG. This is possible because of the 
presence of multiple functional groups susceptible of chemical modification. Heparin is a 
linear, polysulfated and polydispersed polysaccharide composed of -D-glucopyranosiduronic 
acid (glucuronic acid, GlnA) or -L-idopyranosiduronic acid (iduronic acid, IdoA) and N-
acetyl or N-sulfo D-glucosamine (GlcN) with a (1→4) linkage. These residues are variably 
substituted with anionic O-sulfo (sulfate) and N-sulfo (sulfoamino) groups giving the GAG 
a highly negatively charge (-2.7 sulfo groups / disaccharide) (Figure 4).  
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Fig. 4. Chemical structure of heparin. 
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Most of the attempts to modulate protein binding and biological properties of heparin 
have been made by the modulation of the sulfation patterns of the GAG backbone and 
enhance of chain flexibility of the GAG by the glycol-splitting of C2-C3 bonds of 
nonsulfated GlcA and IdoA residues. Both the degree of sulfation (charge density) and the 
appropriate distribution of N-sulfate and N-acetyl groups (charge distribution) along the 
heparin molecule is determinant in its biological properties. For example, the strongest 
protein binding was observed for ‘fully sulfated’ heparin and extra-sulfate groups 
potentiated this interaction. 
Chain flexibility is thought to play a key role in heparin-protein interactions. It is conferred 
by IdoA-containing sequences which are considered to facilitate the appropriate orientation 
of substituents for the suitable interaction (Casu et al., 2002a; Casu et al., 2002b). Additional 
local flexibility was obtained by glycol-splitting that act as flexible joints along the heparin 
chain were conformation changes can be induced by the protein interaction.  
Chemical modifications of heparin have been reviewed in depth by Casu et al. (Casu et al., 
2002b) and Fernandez et al. (Fernández et al., 2006) that described the biological effect of N-
sulfate removal, N-acylation of native amino groups or  amino groups created after N-
desulfation, O-sulfate removal, sulfation of hydroxyl groups (existing in the molecule or 
exposed by desulfation), acylation of unsubstituted hydroxyl groups and glycol-splitting. 
Several groups have dedicated their research activity of the last decades to understand the 
structure-activity relationship of this molecule by its controlled chemical modification. One 
of the most interesting chemically modified heparins was developed by Nagi et al. (Naggi et 
al., 2005) SST0001 (= 100NA-RO.H = HI2), a 100% N-acetylated and 25% glycol-split modified 
heparin (Figure 5), inhibits heparanase and presents non-anticoagulant activity and the 
ability to inhibit metastasis formation in various metastatic tumor animal models and 
activity also in human multiple myeloma models (Ritchie et al., 2011).   
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Fig. 5. Chemical structure of SST0001 (= 100NA-RO.H = HI2), a 100% N-acetylated and 25% 
glycol-split heparin. Heparin was N-acetylated by time-controlled N-desulfation under 
solvolytic conditions. Glycol-split N-acetylated heparin was prepared by exhaustive 
periodate oxidation and borohydride reduction of the resulting dialdehydes. 
Heparanase inhibition decreases heparin-binding growth factor release (FGF, VEGF) from 
ECM via HPGS degradation inhibiting the angiogenesis activity induced by these GF. 
Glycol-splitting causes heparin to lose affinity for antithrombin (GlcA residue in the 
pentasaccharide sequence of the active site for antithrombin is modified) and therefore a 
non-anticoagulant activity. The combination of heparanase inhibition, inhibition of ECM-
bound proangiogenic growth factors release and the non-anticoagulant activity points 
SST0001 as potential antiangiogenic and antimetastatic agent.   
Another heparinoid with negligible anticoagulant activity is ST2184 obtained by controlled 
nitrous acid depolymerization of undersulfated glicol-split ST1514 (Pisano et al., 2005).  
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2.3 Heparin-conjugates  
Heparin has been conjugated to different molecules in order to obtain new drug delivery 
systems and scaffolds for tissue engineering with controlled angiogenic properties. In this 
sense, heparin has been conjugated to chemotherapeutic agents (e.g. paclitaxel), 
hydrophobic moieties (e.g. N-deoxycholyethylenediamine), thermosensitive polymers (e.g. 
Poloxamers) or even proteins (e.g. antithrombin or endostatin) in order to improve drug 
availability, drug targeting, heparin stability or modulate anticoagulant behaviour and 
angiogenic properties.  
Paclitaxel is a widely used chemotherapeutic agent for the treatment of solid carcinomas. 
However, its clinical use is limited by its poor aqueous solubility. Several authors have been 
working in the preparation of new paclitaxel-heparin delivery systems with improved 
chemotherapy efficacy and enhanced antiangiogenic activity. In this sense, Wang et al. 
prepared amphiphilic heparin-paclitaxel prodrugs by covalent conjugation through 
hydrolysable bonds based on a single aminoacid spacer, either valine, leucine or 
phenylalanine (Y. Wang et al., 2009a; Y. Wang et al., 2009b). Heparin (hydrophilic)-paclitaxel 
(hydrophobic) system spontaneously self-assembled in aqueous solution forming 
nanoparticles with appropriate properties for drug delivery applications. These materials 
preserved structural integrity of paclitaxel, presented appropriate drug delivery profiles and 
also enhanced targeting capacity to solid tumors. Park et al. followed a similar strategy and 
conjugated heparin with paclitaxel through an amide linkage and observed comparable 
results (I.K. Park et al., 2010b). 
A ternary conjugate heparin-folic acid-paclitaxel, loaded with additional paclitaxel, was 
developed to specifically target folate receptor that is highly expressed in several types of 
solid tumors, including ovarian, uterine, lung, breast, and head and neck cancers (X. Wang 
et al., 2009). Other ternary system that included folate has been recently developed: 
succinylated heparin conjugated with folate via polyethylene glycol (PEG) 1000/3000 
spacers  (Wang et al., 2010) or heparin-retinoic acid-folic acid conjugates (I.K. Park et al., 2010a). 
These systems displayed amphiphilic properties and formed nanoparticles capable of 
entrapping hydrophobic agents, such as taxol.   
N-deoxycholyethylenediamine (DOCA) was covalently attached to the carboxylic acids of 
heparin (Park et al., 2007) or LMWH Fraxiparin (D.Y. Lee et al., 2009; J.W. Park et al., 2010) 
via amide formation resulting in an amphiphilic system. Heparin-DOCA derivatives 
presented lower anticoagulant activity, but inhibited angiogenesis both in vitro and in mice 
model and were postulated as promising drug carriers due to its amphiphilic structure. 
Moreover, LMWH-DOCA (D.Y. Lee et al., 2009) systems were successfully designed to be 
orally absorbed improving their therapeutical potential, due to DOCA (hydrophobic) 
enhanced the interaction between heparin and the intestinal membrane. Fraxiparin was also 
conjugated with taurocholate giving rise to helical-structured macromolecules with strong 
antiangiogenic activity and significant tumor growth inhibition potencial on SCC7 and 
MDA-MB231 human breast carcinoma cells subcutaneously injected in mice (E. Lee et al., 
2009). 
Tan et al. prepared LMWH-endostatin conjugates in order to obtain a synergistic effect of both 
endostatin (a potent endogenous angiogenesis inhibitor) and LMWH, so better 
antiangiogenesis and antitumor activity of the modified products was observed in vitro (Tan 
et al., 2008) and in vivo using the CAM assay, corneal neovascularization (CNV) assay and 
S180 tumor bearing mice (Tan et al., 2011). LMWH not only acted as a good protein modifier 
(the conjugates presented enhanced heat stability than endostatin, high percentage of 
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retained activity and slight secondary structure alteration), but also played an active role in 
the biological activity of the resulting product.  
Heparin-poloxamer-heparin conjugates were also developed giving rise to self-assembled 
nanoparticles with marked thermosensitivity for drug delivery  (Chung et al., 2010; Tian et 
al., 2010).  
Latent antithrombin was covalently attached to heparin and both the anticoagulant behaviour 
and antiangiogenic activity of the conjugate studied for its application in the treatment of 
the respiratory distress syndrome  (Parmar et al., 2009). The conjugate exerted a selective 
antiproliferative effect on lung fibroblasts and the antiangiogenic effect of latent 
antithrombin was prevented when permanently bound to heparin. Anticoagulant activity of 
antithrombin was not significantly affected by the chemical modification. 
2.4 Biotechnological heparins 
Heparin is a heterogeneous mixture of molecules isolated from animal tissues, historically 
from bovine tissues and currently mostly from porcine tissues. Animal-derived 
pharmaceutical products represent a high risk to humans due to possible animal-to-man 
transmitted diseases (e.g. Creutzfeldt-Jacobs syndrome) and the different chemical structure 
and biological effect depending on the animal source, tissue and purification procedure. 
Moreover, heparin is a minor component in animal tissues and its purification requires high 
volumes of solvents and chemicals. Therefore, new routes to obtain chemically-modified 
heparins in high quantities and homogeneous composition were found in biotechnology 
(Presta et al., 2005). 
K5, a bacterial polysaccharide from Escherichia Coli, presents the same structure as heparin 
biosynthetic precursor and can be tailored modified by combined chemical and enzymatic 
approaches giving rise to a multi-target class of biotechnological heparin/HS-like molecules. 
These products present different biological properties including anticoagulant/ 
antithrombotic, anti-AIDS and antitumor activities (antineoplastic, antiangiogenic, and 
antimetastatic) depending on the performed modification  (Rusnati et al., 2005). 
PI88 (Progen Pharmaceuticals, http://www.progen.com.au/pipeline/angiogenesis.aspx) is 
a phosphosulfomannanopentaose derived from the polysaccharide secreted by the yeast P. 
Holstii (Parish et al., 1999) that not only inhibits heparanase and stimulates TFPI release, but 
also interferes with heparin-binding growth factors inhibiting angiogenesis and metastasis. 
PI88 is currently being evaluated in multiple phase II clinical trials for the treatment of lung 
cancer (NSCLC), primary liver cancer, multiple myeloma and melanoma. 
2.5 Synthetic sulfated oligosaccharides 
Synthetic oligosaccharides are also under investigation as heparin-like compounds with 
antiangiogenic activity.   
Progen Pharmaceuticals has also developed PG500 a series of fully synthetic and fully 
sulfated family of single entity oligosaccharides attached to a lipophilic moiety (aglycone) at 
the reducing end of the molecule. These compounds inhibit FGF-1, FGF-2 and VEGF and 
also heparanase (Dredge et al., 2010).  
Borsig et al. described the heparanase and selectin inhibitory effect of novel semisynthetic 
sulfated trimannose C-C-linked dimmers. These sulfated hexasaccharides mimic maltohexaose 
sulfate, a potent carbohydrate-based heparanase inhibitor currently subjected to phase II/III 
clinical trials in cancer patients (Borsig et al., 2011). 
www.intechopen.com
 
Tumor Angiogenesis 
 
14
3. Synthetic heparin-like compounds 
The polysulfated character of heparin suggests that polymers carring sulfonic groups could 
be a good strategy to sinthesize new antiangiogenic drugs. 
The evolution of heparin-like synthetic drugs started in the early 90’s. A polysulfonated 
naphthylurea (Suramin) was investigated in the inhibition of different proangiogenic factors 
(Danesi et al., 1993; Gagliardi et al., 1992). Based on the structure of suramin, different 
polysulfated and polysulfonic acid polymers were developed with capacity to interact with 
proangiogenic factors in similar mode to heparin (Fernández-Tornero et al., 2003; Liekens et 
al., 1999; Liekens et al., 1997). Actually there are different polyanionic and non-
polysulfonated components under study with capacity to interact with proangiogenic factor 
in the same binding-site that HSPGs (Fernández et al., 2010).  
3.1 Polysulfated/polysulfonated heparin-like compounds 
The mechanism of action of these heparin-like drugs is based on its similarity with heparin 
structure. The sulfate groups of these compounds interact with different heparin-binding 
angiogenic factors in a similar way to heparin and inactivate it thereby preventing induction 
of angiogenesis. 
3.1.1 Suramin 
Suramin is a polysulfonated naphthylurea and an antitrypanosomal agent used since the 
early 1920s for the treatment of onchocerciasis and African sleeping sickness  (Williamson, 
1957; Williamson & Desowitz, 1956). In the early 90’s suramin was investigated in the 
inhibition of different growth factors due to its similarity with heparin. Different researchers 
demonstrated the antagonism character between heparin and suramin and the capacity to 
inhibit different angiogenic factors by preventing their interaction with cell-surface HSPGs 
(Danesi et al., 1993; Gagliardi et al., 1992). This activity is due to the capacity of suramin to 
bind to the  heparin-binding site of the proangiogenic factors via the sulfonate groups 
(Braddock et al., 1994; Middaugh et al., 1992). 
Suramin was employed in the treatment of conventional chemotherapy unresponsive 
tumors (Hawkins, 1995), however high doses were necessary to achieve anti-tumor activity 
which developed  intolerable toxicities (Collins et al., 1986; Constantopoulos et al., 1983). 
In order to improve the activity of suramins and decrease its toxic-side effects, different 
polysulfonated naphthylureas structurally related to suramin were investigated. The results 
demonstrated that modifications in the backbone and the number of sufonic groups had a 
significant effect on angiogenesis inhibition (Manetti et al., 1998; Zamai et al., 1998). All the 
suramin derivatives contain the amido-N-methylpyrrolnaphthalenesulfonic acid group and 
are generally called suradistas. 
Suradistas present a higher inhibition of bFGF-induced mitogenesis on fibroblasts and a 
higher inhibition of the neovascularization of the CAM than suramins (Hassan, 2007). 
3.1.2 Pentosan polysulfate 
Pentosan polysulfate (PPS) is a semi-synthetic pentasaccharide heparinoid derived from 
beech wood shavings. Its activity is also due to the presence of sulfonic groups that interact 
with different heparin-binding growth factors (Zugmaier et al., 1992). PPS has demonstrated 
inhibition of endothelial cell motility, tubule formation in vitro and capillary formation in in 
vivo assay (Nguyen et al., 1993). 
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PPS has been evaluated in the inhibition of cancer and Kaposi’s sarcoma in vitro (Nakamura 
et al., 1992) and, also, in clinical trials phase I/II (Lush et al., 1996), but its clinical application 
has been limited by the high anti-coagulant activity at doses needed to inhibit the 
angiogenesis. 
3.1.3 1,3,6-Naphthalenetrisulfonic acid 
In order to decrease the toxic side-effects of suramin, different derivatives of these 
compounds were studied in the last years. Lozano et al. demonstrated that 1,3,6-
naphthalenetrisulfonic acid (NTS) seem the active part of suramin (Lozano et al., 1998). In 
their studies showed that NTS is an effective inhibitor of the mitogenic activity of aFGF and 
this activity is due to the interaction with aFGF in the heparin binding-site. 
 
 
Fig. 6. NTS-based compounds studied by Fernández-Tornero et al. 
The union of NTS to aFGF causes a displacement in the aminoacids and creates a cavity in 
the surface of NTS-bound aFGF. This cavity increases the solvent accessibility of this inner 
core and stabilizes the molecule, in this conformation the aFGF become inactive to activate 
the angiogenic process. 
In the last years, Fernández Tornero et al. studied different compound derived from NTS 
with different numbers of sulfonic groups and substituents (Figure 6) (Fernández-Tornero et 
al., 2003). 
5-amino-2-naphthalenesulfonic acid (ANSA) showed the best antiangiogenic activity and 
lower toxicity. The activity was related to the capacity to interact with heparin-binding site 
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of FGF due to the presence of the sulfonic acid group (Figure 7). In this case ANSA binds in 
a 1:1 stoichiometric ratio to a positively charged cavity at the surface of FGF (some of the 
basic residues implicated in the interaction of this protein with heparin) by the sulfonate and 
the amino groups. This interaction prevents the union between FGF and heparin and 
inhibits the activation of angiogenic process. This compound has been recently used to 
synthesize new sulfonic acid-bearing polymers with antiangiogenic activity (Garcia-
Fernandez et al., 2010a; Garcia-Fernandez et al., 2010b) as described in the next section. 
 
 
 
Fig. 7. A complex between acidic fibroblast growth factor and ANSA. ANSA is shown as 
stick-and-ball model (carbon: grey; oxygen: red; sulfur: yellow; nitrogen: blue). The figure 
was generated and the surfaces colored according the electrostatic potential (red, negative; 
blue, positive) using OpenAstexViewer (3.0; Astex Therapeutics Ltd.) and its internal 
parameters. PDB ID: 1HKN (Fernández-Tornero et al., 2003). 
3.1.4 Sulfonic acid polymers 
The synthesis of polymers with a heparin-like structure is a recent way to obtain polymers and 
copolymers with antiangiogenic activity. Liekens et al. (Bugatti et al., 2007; Liekens et al., 1999; 
Liekens et al., 1997) studied different sulfonic acid-bearing polymers and demonstrated their 
capacity to impair the binding of bFGF to HSPGs.  In these studies different polymers  (poly(2-
acrylamido-2-methyl-1-propanesulfonic acid) (polyAMPS), poly(anetholesulfonic acid) and 
poly(4-styrenesulfonic acid)) showed a inhibition of the aFGF-mediated mitogenic response. 
The highest antiangiogenic activity was obtained for polyAMPS and the study of its 
intereaction with FGF showed that in the polymerization each AMPS units develops several 
intramolecular hydrogen bonds between adjacent acrylamido units producing a helical 
structure similar to heparin with the sulfonate groups spaced 9-10 Å. 
In the last years García-Fernández et al. developed different families of new polysulfonic 
acid copolymers based on AMPS and a methacrylic derivative of ANSA (MANSA) (Garcia-
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Fernandez et al., 2010a; Garcia-Fernandez et al., 2010b; Garcia-Fernandez et al., 2010c). Two 
different families of copolymers with N-vinylpyrrolidone (hydrophilic, VP) and 
butylacrylate (hydrophobic, BA) were synthesised in order to obtain different properties in 
aqueous media. The highest antiangiogenic activity was obtained for the hydrophobic 
MANSA copolymers (poly(BA-co-MANSA)) due to the formation of an interesting micellar 
morphology by self-assembling with the hydrophilic MANSA units located on the surface of 
the micelle. This organization provides an optimal orientation of the sulfonic acid groups for 
the interaction with the growth factor. This gives an increasing inhibitory bioactivity of the 
poly(BA-co-MANSA) with the concentration. 
3.2 Other polyanionic compounds 
Besides the molecules described above, various non-sulfated polyanionic compounds have 
been investigated. For example, aurintricarboxylic acid (Figure 8) showed inhibition of 
heparin-stimulated angiogenesis in the CAM (Gagliardi & Collins, 1994) or RG-13577 (a 
linear polymer of carboxylated phenol-based monomers) prevented microvessel outgrowth 
from rat aortic rings embedded in a collagen gel (Miao et al., 1997).  
 
 
 
Fig. 8. Polyanionic compounds with antiangiogenic activity (aurintricarboxylic acid, gentisic 
acid and homogentisic acid).  
But the most promising polyanionic compounds are gentisic (a widespread plant secondary 
metabolite, GA) and homogentisic acid (the toxic agent in alkaptonuria, HGA) (Fernández et 
al., 2010) (Figure 8).  
These compounds present higher antiangiogenic activity than ANSA and other sulfonic 
compounds both in vivo and in vitro. Both, GA and HGA bind in a 1:1 stoichiometric ratio to 
a positively charged cavity at the surface of FGF (part of the long cationic hearing-binding 
site) (Figure 9). 
ANSA, GA, and HGA bind to the same site, these results were unexpected because these 
compounds are chemically unrelated. The relative positions of the hydroxyl groups in the 
aromatic ring stabilized the molecules by a network of non-covalent contacts. This 
inactivates FGF and blocks FGF-dependent angiogenesis. 
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Fig. 9. A complex between acidic fibroblast growth factor and GA. GA is shown as stick-
and-ball model (carbon: grey; oxygen: red). The figure was generated and the surfaces 
colored according the electrostatic potential (red, negative; blue, positive) using 
OpenAstexViewer (3.0; Astex Therapeutics Ltd.) and its internal parameters. PDB ID: 3JUT 
(Fernández et al., 2010). 
4. Conclusions 
Heparin-like molecules that inhibit proangiogenic molecules through heparin-binding 
domains constitute an effective tool for the design of broad-spectrum antiangiogenic drugs. 
Different types of these molecules were described in this chapter, i.e. heparin species 
(heparinoids, chemically modified heparins, heparin conjugates, biotechnological heparins, 
and synthetic sulfated oligosaccharides) and synthetic heparin-like compounds. Both offer 
endless possibilities for the development of optimized antiangiogenic drugs using the 
organic chemistry procedures.  
On the one hand, numerous heparin species have demonstrated their antiangiogenic 
activity, however it depends on a great number of factors like molecular weight, 
composition (saccharide units concentration), physicochemical properties (such as 
flexibility), charge density (degree of sulfation) and charge distribution, chemical 
modification, conjugated molecule, etc. Currently, for example, it is unknown which 
commercial LMWH and ULMWH have the greatest antiangiogenic effect in cancer patients. 
Therefore, systematic experimental studies of the angiogenesis-modulating effect of heparin 
species and comparative and complete clinical studies are needed in the future  (Debergh et 
al., 2010; Dogan et al., 2011; Mousa & Petersen, 2009; Norrby, 2006). 
On the other hand, synthetic heparin like compounds have been developed using systematic 
routines in order to rationally identify the best activity/toxicity ratio. However, few of these 
products are currently in clinical trials and still need FDA approval. 
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